GlobeNewswire: DiamiR Biosciences Contains the last 10 of 2 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:09:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/11/14/1185681/0/en/DiamiR-Announces-Publication-of-Data-on-microRNA-Biomarkers-for-Neurodegenerative-Diseases-in-Alzheimer-s-Research-Therapy.html?f=22&fvtc=4&fvtv=40536DiamiR Announces Publication of Data on microRNA Biomarkers for Neurodegenerative Diseases in Alzheimer’s Research & Therapy2017-11-14T11:02:00Z<![CDATA[MONMOUTH JUNCTION, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today the publication of "Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases" in Alzheimer’s Research & Therapy [https://doi.org/10.1186/s13195-017-0316-0].]]>https://www.globenewswire.com/news-release/2017/11/01/1172188/0/en/DiamiR-Announces-Poster-Presentation-at-CTAD-2017.html?f=22&fvtc=4&fvtv=40536DiamiR Announces Poster Presentation at CTAD 20172017-11-01T12:02:00Z<![CDATA[MONMOUTH JUNCTION, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira Sheinerman, PhD, Chief Executive Officer, will be presenting at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) being held November 1-4, 2017 in Boston, MA.]]>